Special Issue
CRISPR and Gene Editing in Disease Treatment: From Bench to Bedside
Editor:
Azza Moustafa Fahmy
Department of Parasitology
Immunology and Therapeutic Evaluation Division
Theodor Bilharz Research Institute
Giza, Egypt
Submission Deadline: November 29, 2026
Gene editing has moved rapidly from a powerful laboratory concept to a serious clinical platform with the potential to transform disease treatment. CRISPR-Cas systems and newer tools such as base and prime editing are reshaping how researchers approach pathogenic mutations, immune engineering, and targeted therapeutic development.
This special issue will explore the current state of the art in CRISPR and gene editing, with particular attention to the translational path from experimental innovation to real-world clinical application. We welcome contributions addressing both the promise and the practical challenges of using gene editing to treat monogenic, complex, infectious, inflammatory, and malignant diseases.
Areas of interest include, but are not limited to:
- next-generation editing technologies
- AI-assisted guide RNA design and off-target prediction
- CRISPR applications in oncology, CAR-T engineering, and hematologic disorders
- gene editing in infectious and autoimmune disease
- delivery systems including viral and non-viral platforms
We encourage original research articles, systematic reviews, meta-analyses, and perspectives that provide clinically relevant insights and advance evidence-based interdisciplinary practice.
TIJFS is globally distributed through its online, open-access platform, allowing unrestricted access to readers worldwide. Please follow instructions for authors to submit to this special issue. Authors must choose this special issue at time of submission to be considered in this special issue. We look forward to your contribution. APCs information can be accessed here. Additional waivers or discounts can be granted to authors with special circumstances.
For any questions, feel free to reach out editorial office at editor@tijfs.org.